#jak-inhibition — top 20, last 30d
| 9 | ℹ |
A phase 2, open-label, single-arm clinical trial of the safety and efficacy of the JAK1/3 inhibitor tofacitinib in Down syndrome.
(linkinghub.elsevier.com)
|
Cell Reports Medicine 2026-11-17 | #immunity #down syndrome #clinical trial #jak-inhibition #proteomics |